PENTASA is indicated for the treatment of ulcerative colitis, proctitis, proctosigmoiditis, and also to prevent the symptoms of ulcerative colitis from recurring.
At per Shire’s request, preparations are underway at Prasco to market the authorized generic version of PENTASA (mesalamine) Controlled-Release Capsules, immediately upon any entrance of an approved ANDA for any generic mesalamine product into the US market.
The authorized generic is to be marketed in the US in 250 mg and 500 mg strengths under the Prasco label.
Prasco CEO Thomas Arington said both patients and pharmacists will benefit through the new relationship with Shire which lives by its commitment to maintain the supply of brand-identical medication through the Prasco Authorized Generic business model.